These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1052 related items for PubMed ID: 21597022

  • 1. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):863-75. PubMed ID: 21597022
    [Abstract] [Full Text] [Related]

  • 2. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.
    Ann Oncol; 2019 Sep 01; 30(9):1466-1471. PubMed ID: 31268130
    [Abstract] [Full Text] [Related]

  • 3. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.
    Gastroenterology; 2015 Jan 01; 148(1):88-99. PubMed ID: 25305506
    [Abstract] [Full Text] [Related]

  • 4. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE, Hong YS, Kim HJ, Kim KP, Lee JL, Park SJ, Lim SB, Park IJ, Kim CW, Yoon YS, Yu CS, Kim JC, Hoon KJ, Kim TW.
    Ann Surg Oncol; 2015 Dec 01; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [Abstract] [Full Text] [Related]

  • 5. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.
    JAMA Oncol; 2017 Apr 01; 3(4):472-480. PubMed ID: 28006055
    [Abstract] [Full Text] [Related]

  • 6. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A, Akewanlop C.
    World J Gastroenterol; 2015 Jan 21; 21(3):926-34. PubMed ID: 25624727
    [Abstract] [Full Text] [Related]

  • 7. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
    Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.
    Zhonghua Zhong Liu Za Zhi; 2015 Aug 21; 37(8):591-6. PubMed ID: 26714599
    [Abstract] [Full Text] [Related]

  • 8. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.
    J Clin Oncol; 2010 Jul 10; 28(20):3219-26. PubMed ID: 20498393
    [Abstract] [Full Text] [Related]

  • 9. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.
    JAMA Oncol; 2018 Mar 01; 4(3):379-383. PubMed ID: 28983557
    [Abstract] [Full Text] [Related]

  • 10. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.
    J Clin Oncol; 2013 Oct 10; 31(29):3664-72. PubMed ID: 24019539
    [Abstract] [Full Text] [Related]

  • 11. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q, Zhou AP, Yang L, Xu C, Sun YK, Zhang W, Wang JW, Zhong DS.
    J Physiol Pharmacol; 2020 Aug 10; 71(4):. PubMed ID: 33316771
    [Abstract] [Full Text] [Related]

  • 12. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.
    Zhonghua Zhong Liu Za Zhi; 2014 Nov 10; 36(11):844-8. PubMed ID: 25620482
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.
    J Clin Oncol; 2015 Dec 10; 33(35):4176-87. PubMed ID: 26527776
    [Abstract] [Full Text] [Related]

  • 14. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
    Ma J, Zhang Y, Shen H, Kapesa L, Liu W, Zeng M, Zeng S.
    Tumour Biol; 2015 Dec 10; 36(12):9599-609. PubMed ID: 26142736
    [Abstract] [Full Text] [Related]

  • 15. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F, Li E, Shen G, Dong Q, Ren D, Wang M, Zhao Y, Liu Z, Ma J, Xie Q, Liu Z, Li Z, Gao L, Zhao J.
    J Gastroenterol; 2023 Jul 10; 58(7):622-632. PubMed ID: 37036516
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA.
    J Natl Cancer Inst; 2017 May 10; 109(5):. PubMed ID: 28040692
    [Abstract] [Full Text] [Related]

  • 17. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P.
    J Clin Oncol; 2011 Apr 01; 29(10):1261-70. PubMed ID: 21383284
    [Abstract] [Full Text] [Related]

  • 18. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K, Edler D, Hallström M, Ragnhammar P.
    Acta Oncol; 2010 Aug 01; 49(6):797-804. PubMed ID: 20307245
    [Abstract] [Full Text] [Related]

  • 19. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
    Cancer Chemother Pharmacol; 2010 Sep 01; 66(4):659-67. PubMed ID: 20033812
    [Abstract] [Full Text] [Related]

  • 20. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
    Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Krieken JH.
    Br J Cancer; 2009 Jan 27; 100(2):266-73. PubMed ID: 19165197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.